Pimecrolimus/paclitaxel-eluting coronary stent - Johnson & Johnson

Drug Profile

Pimecrolimus/paclitaxel-eluting coronary stent - Johnson & Johnson

Alternative Names: Paclitaxel/pimecrolimus-eluting coronary stent - Johnson & Johnson; Symbio

Latest Information Update: 17 Feb 2016

Price : $50

At a glance

  • Originator Conor Medsystems
  • Developer Conor Medsystems; Cordis Corporation
  • Class Anti-inflammatories; Diterpenes; Macrolides; Paclitaxels; Taxanes
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Coronary artery disease

Most Recent Events

  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in Belgium (Intracoronary)
  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in United Kingdom (Intracoronary)
  • 17 Feb 2016 No development reported - Phase-III for Coronary artery disease in Israel (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top